144 ·Filed May 28, 2026

ANAB

ANAPTYSBIO, INC
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago SEC0001950047-26-005251
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

The officer's consistent selling over two weeks is notable but not alarming given the modest size relative to market cap (~0.035% of shares outstanding). Monitor for any acceleration of insider sales or a Form 4 filing confirming execution. No immediate trading catalyst.

DirectionNeutral
Confidencemedium
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
ANAB ▲ +4.98% at T+60d
NEUTRAL call ✓ call won +4.98% · α vs SPY +3.79% · entry $55.67 → $58.44
Entry anchored
May 28, 2026
via day open
T+1d
-4.54%
call -4.54% · α -4.80%
$53.14
settled 4mo ago
T+5d
-9.52%
call -9.52% · α -7.00%
$50.37
settled 4mo ago
T+20d
+18.50%
call +18.50% · α +20.30%
$65.97
settled 3mo ago
T+60d
+4.98%
call +4.98% · α +3.79%
$58.44
settled 6w ago

Price Chart

Loading chart...

Executive Summary

Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on May 28, 2026, indicating intent to sell 10,264 shares of common stock valued at approximately $594,671. The proposed sale follows a series of recent open-market sales totaling 75,467 shares for about $4.3 million between May 15 and May 27, 2026, and is tied to a stock option exercise. While the filing signals insider intent to monetize equity, the officer has been a consistent seller over the past two weeks, which may raise mild concern but is not unusual for routine option exercises and diversification.

Key Facts

  • Officer Dennis Mulroy filed Form 144 on May 28, 2026, to sell 10,264 shares of common stock.
  • The proposed sale has an approximate market value of $594,671 based on a $57.93 per share price.
  • The shares to be sold are from a stock option exercise executed on May 28, 2026.
  • Mulroy has sold 75,467 shares in seven separate transactions between May 15 and May 27, 2026, totaling approximately $4.3 million.
  • The filing is an advance notice of intent to sell; the actual sale may not occur.
  • AnaptysBio has a market cap of $1.7 billion and analyst consensus is 89% bullish (16 Buy, 2 Hold).

Financial Impact

Proposed sale of 10,264 shares valued at ~$594,671; cumulative recent sales of 75,467 shares for ~$4.3 million.

dilution

Risk Factors

  • Insider selling may signal lack of confidence if it accelerates or becomes material relative to holdings.
  • Form 144 is only an intent to sell; the sale may not be executed.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (18 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005251
Document: 0001950047-26-005251-index.html0001950047-26-005251
Document: 0001950047-26-005251.txt0001950047-26-005251
24 reports for ANAB
Performance horizon
67% Hit rate 12 of 18 directional calls best @ T+60▲ +41.26%Mar 3, 2026
Filters
Rows
Reports for ANAB — sortable, filterable
TypeNow
Aug 12, 2026
7w ago
Institutional Cluster
BULLISH ★ 5/10
$56.02 $53.87▼ −3.84%▼ −2.09%$48.53 (−13.37%)
Jun 29, 2026
13w ago
144
BEARISH ★ 6/10
$67.50 $53.61▲ +20.58%▲ +19.55%$48.53 (+28.10%)
Jun 29, 2026
13w ago
DEFA14A
NEUTRAL ★ 2/10
$67.50 $53.61▼ −20.58%▼ −19.55%$48.53 (−28.10%)
Jun 26, 2026
14w ago
144
BEARISH ★ 6/10
$65.97 $54.15▲ +17.92%▲ +17.64%$48.53 (+26.44%)
Jun 22, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$59.43 $50.29▼ −15.38%▼ −16.54%$48.53 (−18.34%)
Jun 17, 2026
15w ago
144
BEARISH ★ 5/10
$57.51 $54.15▲ +5.84%▲ +6.38%$48.53 (+15.61%)
Jun 15, 2026
15w ago
144
BEARISH ★ 6/10
$57.61 $62.51▼ −8.51%▼ −8.31%$48.53 (+15.76%)
Jun 11, 2026
16w ago
144
BEARISH ★ 6/10
$56.07 $66.39▼ −18.41%▼ −16.63%$48.53 (+13.45%)
Jun 10, 2026
16w ago
144
BEARISH ★ 5/10
$54.24 $66.59▼ −22.77%▼ −20.88%$48.53 (+10.53%)
Jun 8, 2026
16w ago
144
BEARISH ★ 5/10
$51.63 $67.33▼ −30.40%▼ −28.95%$48.53 (+6.00%)
Showing 10 of 24

US Market Status

Market Closed — Opens Mon (38h 32m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access